Enteropathy-associated T-cell lymphoma screening: Difference between revisions
Nima Nasiri (talk | contribs) |
Nima Nasiri (talk | contribs) No edit summary |
||
| (5 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Enteropathy-associated T-cell lymphoma}} | {{Enteropathy-associated T-cell lymphoma}} | ||
{{CMG}}; {{AE}} {{AS}} | {{CMG}}; {{AE}}{{Nnasiri}} {{AS}} | ||
==Overview== | ==Overview== | ||
Enteropathy-associated T cell lymphoma is a very rare but aggressive disease, an extranodal form of [[non-Hodgkin lymphoma]] which has two subtypes, type I is associated with [[celiac disease]] and more common in the western population, type II is more common in Asian countries. | |||
==Screening== | ==Screening== | ||
*There is insufficient evidence to recommend routine screening for enteropathy-associated T-cell lymphoma. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Latest revision as of 15:13, 10 January 2019
|
Enteropathy-associated T-cell lymphoma Microchapters |
|
Differentiating Enteropathy-associated T-cell lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Enteropathy-associated T-cell lymphoma screening On the Web |
|
American Roentgen Ray Society Images of Enteropathy-associated T-cell lymphoma screening |
|
Enteropathy-associated T-cell lymphoma screening in the news |
|
Risk calculators and risk factors for Enteropathy-associated T-cell lymphoma screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Nima Nasiri, M.D.[2] Sowminya Arikapudi, M.B,B.S. [3]
Overview
Enteropathy-associated T cell lymphoma is a very rare but aggressive disease, an extranodal form of non-Hodgkin lymphoma which has two subtypes, type I is associated with celiac disease and more common in the western population, type II is more common in Asian countries.
Screening
- There is insufficient evidence to recommend routine screening for enteropathy-associated T-cell lymphoma.